HLA-DR expression by labial minor salivary gland tissues in Sjögren’s syndrome

H M Moutsopoulos, J J Hooks, C C Chan, Y A Dalavanga, F N Skopoili, and B Detrick

From the Department of Medicine, Medical School, University of Ioannina, 453 32 Ioannina, Greece; and the Immunology and Virology Section, National Eye Institute, NIH, Bethesda, Maryland, USA

Summary Minor salivary gland biopsy specimens from patients with Sjögren’s syndrome (primary and secondary) and from normal controls were examined with the four step biotin-avidin-immunoperoxidase assay. The composition of the infiltrating cells was similar in patients with both primary and secondary Sjögren’s syndrome, consisting primarily of T helper/inducer cells. B lymphocytes (Leu-14) were approximately 20–35% of the infiltrating lymphocytes, while only a few OKM1 (monocytes/macrophages) and Leu-7+ (natural killer; NK) cells were observed. The majority of infiltrating lymphocytes expressed HLA-DR antigens. In the biopsy specimens of the controls there were no infiltrates; the scattered lymphocytes, however, were also predominantly T lymphocytes. Finally, the glandular epithelial cells (ducts and acini) were inappropriately expressing HLA-DR antigens, in contrast with controls where minimal HLA-DR expression was found.

Key words: T lymphocytes, epithelial cells.

Sjögren’s syndrome (SS) is the result of a chronic, persistent, lymphocytic infiltrate of exocrine glands, which leads to diminished glandular secretions and mucosal dryness.

Two major phenomena characterise this disease as autoimmune: the chronic focal or diffuse lymphocytic infiltrate and B lymphocyte hyperreactivity expressed as hypergammaglobulinaemia, autoantibodies, and immune complexes. Initial studies have shown that this infiltrate consists of T and B lymphocytes. Using monoclonal antibodies, however, it was shown that the cell which predominates in the infiltrate of the exocrine glands is the T helper/inducer cell. The triggering factor of this infiltrate remains obscure.

Class II major histocompatibility antigens have a key role in antigen presentation and regulation of the immune response. Sjögren’s syndrome is one of the autoimmune diseases which is highly associated with class II HLA antigens. These antigens are normally expressed on macrophages, B lymphocytes, activated T lymphocytes, and capillary endothelium. Recently, inappropriately expressed HLA-DR expression was noticed in thyrocytes and epithelial or endothelial cells of affected tissues in inflammatory and autoimmune states.

In the present report we show that minor salivary gland tissues from patients with Sjögren’s syndrome inappropriately express HLA-DR antigens; a finding which suggests that the altered glandular tissue in Sjögren’s syndrome may have a role in the pathogenesis of the disease.

Patients and methods

Patients Sixteen minor labial salivary gland biopsy specimens were obtained from seven patients with primary Sjögren’s syndrome (pSS), three patients with rheumatoid arthritis (RA) and clinical and histological evidence of SS, two patients with RA without clinical or histological manifestations of SS, one patient with systemic lupus erythematosus (SLE) and SS, and three normal volunteers. The specimens were immediately embedded in OCT (Miles Lab., Naperville, II11), snap frozen in a
mixture of dry ice/2-methylbutane (−75°C), and stored at −70°C until processed. The biopsy specimens from patients with SS had different degrees of histopathological lesion according to Tarpley's classification17 (Table 1). Three biopsy specimens from the normal volunteers and the two specimens from the RA patients did not have the classical histopathological lesion of SS but only scattered

Table 1 Tarpley’s classification of the labial minor salivary gland histopathological lesion

<table>
<thead>
<tr>
<th>Class</th>
<th>Histopathological lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal salivary tissue</td>
</tr>
<tr>
<td>I (1+)</td>
<td>Round cell aggregates* (one or two) of lymphocytes, plasma cells, and histiocytes per lobule</td>
</tr>
<tr>
<td>II (2+)</td>
<td>More than three aggregates of round cells per lobule</td>
</tr>
<tr>
<td>III (3+)</td>
<td>Diffuse lobular round cell infiltrates with partial destruction of acinar tissue, with or without fibrosis</td>
</tr>
<tr>
<td>IV (4+)</td>
<td>Diffuse round cell infiltrate with fibrosis destroying completely the lobular architecture</td>
</tr>
</tbody>
</table>

*Aggregate=approximately 50 round cells.

Table 2 Clinical profile of individuals participating in the study

<table>
<thead>
<tr>
<th>No</th>
<th>Diagnosis</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Disease duration (years)</th>
<th>Minor labial salivary gland histopathology (Tarpley’s classification)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal</td>
<td>50</td>
<td>F</td>
<td>NA*</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>Normal</td>
<td>58</td>
<td>F</td>
<td>NA</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Normal</td>
<td>42</td>
<td>F</td>
<td>NA</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>RA</td>
<td>48</td>
<td>F</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>RA</td>
<td>33</td>
<td>F</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>SS</td>
<td>53</td>
<td>F</td>
<td>4</td>
<td>4+</td>
</tr>
<tr>
<td>7</td>
<td>SS</td>
<td>48</td>
<td>F</td>
<td>7</td>
<td>2+ (fibrosis)</td>
</tr>
<tr>
<td>8</td>
<td>SS</td>
<td>57</td>
<td>F</td>
<td>12</td>
<td>2+ (fibrosis)</td>
</tr>
<tr>
<td>9</td>
<td>SS</td>
<td>49</td>
<td>F</td>
<td>2</td>
<td>4+ (severe fibrosis)</td>
</tr>
<tr>
<td>10</td>
<td>SS</td>
<td>38</td>
<td>F</td>
<td>5</td>
<td>4+</td>
</tr>
<tr>
<td>11</td>
<td>SS</td>
<td>70</td>
<td>F</td>
<td>10</td>
<td>1+</td>
</tr>
<tr>
<td>12</td>
<td>SS</td>
<td>50</td>
<td>F</td>
<td>12</td>
<td>2+</td>
</tr>
<tr>
<td>13</td>
<td>RA+SS</td>
<td>52</td>
<td>M</td>
<td>7</td>
<td>3+ (fibrosis)</td>
</tr>
<tr>
<td>14</td>
<td>RA+SS</td>
<td>59</td>
<td>F</td>
<td>1</td>
<td>3+</td>
</tr>
<tr>
<td>15</td>
<td>RA+SS</td>
<td>56</td>
<td>F</td>
<td>8</td>
<td>1+</td>
</tr>
<tr>
<td>16</td>
<td>SLE+SS</td>
<td>48</td>
<td>F</td>
<td>6</td>
<td>2+</td>
</tr>
</tbody>
</table>

*NA=not applicable.
lymphocytes throughout the gland. Table 2 summarises the clinical data of these patients and the histological findings in the minor salivary gland biopsy specimens.

**STAINING PROCEDURE**

Serial frozen sections (4 μm) were cut and placed on gelatinised slides, which were stored at -70°C. Before staining, the slides were air dried for 20 min at room temperature and fixed in acetone. Mouse hybridoma derived monoclonal antibodies against human T lymphocytes (Leu-4), T helper cells (Leu-3a), T helper/inducer cells (Leu-8), T suppressor/cytotoxic cells (Leu-2a), B lymphocytes (Leu-14), NK cells (Leu-7) (Becton-Dickinson Monoclonal Center, Inc., Mountain View, California), macrophages/monocytes (OKM1), and HLA-DR antigen (OKIa), (Ortho Diagnostic Systems Inc., Raritan, New Jersey) were used as primary antibody at a dilution of 1:40. Mouse ascites protein was also used as a control protein. After incubation in a moist chamber at room temperature for one hour the slides were washed in TRIS (trometamol) buffered saline, and the secondary antibody, biotin labelled horse antimouse IgG (ABC kit, Vectastain, Vector Lab., Burlingame, Ca) 1:200 was added. The slides were incubated in the moist chamber at room temperature for another hour. After washing in TRIS buffered saline avidin-biotin-peroxidase complex (Vector Lab.) 1:100 was applied for 45 min. The slides were then washed in TRIS buffered saline, allowed to react with the substrate of diaminobenzidine 8%, Ni2SO4 3%, H2O2 solution, counterstained with methyl green, dehydrated, cleared, mounted, and a coverslip added as in routine processing.

**DATA COLLECTION**

The minor salivary gland frozen sections were read in a blind fashion and scored independently by two
observers, using 40× magnification. The number of
cells labelled with each monoclonal antibody was
counted for at least 10 different fields and averaged.
Special attention was paid to the staining by the
different antibodies of the glandular tissue (acini
and ducts). Cells were considered positive if they
showed a dense, dark black-bluish ring on the
cellular membrane. After the cells were counted the
results from the two observers were averaged. The
variability between the two observers was less than
5%. The mean ratios of T cells to B cells, T cell
subsets (Leu-3a to Leu-2a, Leu-3a to Leu-8), T cells
to NK cells, T cells to macrophages, and HLA-DR
positive to HLA-DR negative acini and ducts were
calculated and recorded.

Results

Eleven out of the 16 biopsy specimens showed
lymphocytic infiltration ranging from 1+ to 4+
according to Tarpley's classification. Four of these
biopsy specimens showed moderate to severe fibro-
sis (Table 2). The other five biopsy specimens
showed normal salivary tissues with scattered lymphocytes.

In the biopsy specimens from SS patients with and
without RA and SLE the predominant cells (55-75%) among either the focal or diffuse infiltrates were cells bearing the pan T lymphocyte marker (Leu-4+). Approximately 20-35% of the infiltrating lymphocytes displayed the B cell marker (Leu-14+). The majority of T lymphocytes expressed the T helper/inducer phenotype (Leu-3a+/Leu-8+). The ratio of Leu-3a+/Leu-2a+ varied from case to case, ranging from 5/1 to 10/1. Among T helper/inducer cells 30-60% also expressed a T inducer phenotype (Leu-8a+). Only a few OKM1+ cells were observed and NK cells (Leu-7+) were rarely detected (Table 3).

Specimens from normal individuals or patients
with RA without SS contained scattered lymphocytes which expressed the pan T marker, with a ratio
HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome

Table 3  Reactivity of the lymphocytes in the infiltrates of the labial minor salivary glands with monoclonal antibodies

<table>
<thead>
<tr>
<th>Monoclonal antibodies</th>
<th>Stained cells (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu-4</td>
<td>pan T lymphocytes</td>
</tr>
<tr>
<td></td>
<td>55-75</td>
</tr>
<tr>
<td>Leu-3a</td>
<td>T helper cells</td>
</tr>
<tr>
<td></td>
<td>45-55</td>
</tr>
<tr>
<td>Leu-2a</td>
<td>T suppressor/cytotoxic cells</td>
</tr>
<tr>
<td></td>
<td>10-20</td>
</tr>
<tr>
<td>Leu-14</td>
<td>pan B lymphocytes</td>
</tr>
<tr>
<td></td>
<td>20-35</td>
</tr>
<tr>
<td>Leu-7</td>
<td>NK cells</td>
</tr>
<tr>
<td></td>
<td>&lt;5</td>
</tr>
<tr>
<td>OKM1</td>
<td>macrophages/monocytes</td>
</tr>
<tr>
<td></td>
<td>&lt;5</td>
</tr>
<tr>
<td>OKIa</td>
<td>HLA-DR</td>
</tr>
<tr>
<td></td>
<td>70-100</td>
</tr>
</tbody>
</table>

In all of the specimens from SS patients more than 70% of the total infiltrating cells expressed HLA-DR antigen (70-100%) (Table 4). In eight specimens 70-90% of the glandular cells expressed HLA-DR antigen. In the remaining three specimens 30-45% of glandular cells expressed HLA-DR antigens. The staining intensity and the incidence of the staining were similar in both ducts and acini. Minimal HLA-DR antigen expression was noted in the glandular ductal and acinar cells of normal individuals of RA patients without SS. The composition of the lymphocytic infiltrate and the epithelial HLA-DR expression in a patient with SS are shown in Figs 1a–1h.

Fig. 1  Minor salivary gland biopsy specimen from SS patient (No 6). (a) Heavy periductal lymphocytic infiltrate destroying the acini (haematoxylin and eosin stain, ×10). Cryostat section of the above biopsy stained with: (b) Mouse ascites protein as a negative control. No staining is observed (×10). (c) Anti-T lymphocyte antibody (Leu-4); 70% of the infiltrating cells are stained (×10). (d) Anti-T helper lymphocyte antibody (Leu-3a); 50% of the infiltrating cells are stained (×10). (e) Anti-T suppressor lymphocyte antibody (Leu-2a); 20% of infiltrating cells are stained (×10). (f) Anti-B lymphocyte antibody (Leu-14); 25% of the infiltrating cells are stained (×10). (g) Antimonocyte/macrophage antibody (OKM1). A few scattered cells are stained (×10). (h) Anti-HLA-DR antibody (OKIa). Intensive staining of the epithelial (ducts and acini) and infiltrating cells is shown (×10).
Table 4  DR expression in lymphocytic infiltrates and glandular tissues (ducts and acini)

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Stained cells with OKIα (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lymphocytic infiltrates</td>
</tr>
<tr>
<td>Normal controls</td>
<td>—</td>
</tr>
<tr>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>—</td>
</tr>
<tr>
<td>RA patients</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>—</td>
</tr>
<tr>
<td>SS patients</td>
<td>60</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
</tr>
<tr>
<td>8</td>
<td>95</td>
</tr>
<tr>
<td>9</td>
<td>80</td>
</tr>
<tr>
<td>10</td>
<td>90</td>
</tr>
<tr>
<td>11</td>
<td>90</td>
</tr>
<tr>
<td>12</td>
<td>90</td>
</tr>
<tr>
<td>RA+SS patients</td>
<td>13</td>
</tr>
<tr>
<td>14</td>
<td>95</td>
</tr>
<tr>
<td>15</td>
<td>95</td>
</tr>
<tr>
<td>SLE+SS patients</td>
<td>16</td>
</tr>
</tbody>
</table>

**Discussion**

Several investigators have studied the circulating lymphocytes and their immunoregulatory subsets in patients in an attempt to determine the aetiology of the B lymphocyte hyper-reactivity in this syndrome. None of these studies, however, could adequately explain this aberration. Moutsopoulos and Fauci described a reversible T suppressor cell defect which did not interfere with the suppressive function of these cells. Fox et al using monoclonal antibodies showed a decreased T suppressor cell population and normal T helper cells. Fauri and Moutsopoulos studying the spontaneous B cell activation in SS and SLE patients showed that activated B cells do not circulate and are not found in the bone marrow of SS patients, in contrast with SLE where the activated B cells were present in both compartments. Lane et al suggested that the affected exocrine glands are one site of localised B cell hyper-reactivity in SS patients. This study and the availability of monoclonal immunoglobulins to lymphocyte surface markers stimulated investigators in this field to study the cell composition in the minor salivary glands of SS patients.

As has been previously shown, and confirmed in our study, the majority of the infiltrating cells in the minor salivary glands were T lymphocytes of the helper/inducer subset and approximately 25% were B lymphocytes. Almost all infiltrating cells displayed the HLA-DR antigen. HLA-DR antigens are expressed mainly by B lymphocytes, monocytes/macrophages, and in vitro by activated T lymphocytes. Most of the infiltrating cells in the minor salivary gland lesion of SS express HLA-DR antigen. Since the majority of these cells are T lymphocytes we suggest that they are activated T lymphocytes. This finding could explain the previously described localised B lymphocyte hyper-reactivity in SS patients.

With the monoclonal antibodies OKM1 and Leu-7 less than 5% of the infiltrating cells were stained. In the haematoxylin and eosin stained slides from SS patients polymorphonuclear leucocytes were not observed. Thus the small numbers of cells stained with OKM1 most probably represent monocytes/macrophages.

The absence of macrophages in the histological lesion of SS can be explained on two grounds. One possibility is that a macrophage defect exists in this syndrome. Previous studies have actually indicated that macrophages are defective in patients with SS. Hamburger et al showed a defective clearance of immune complexes through the Fc receptor of the cells of the reticuloendothelial system in patients with extraglandular SS. Miyasaka et al reported a deficient response in autologous and allogeneic mixed lymphocyte reactions in some patients with SS. This finding suggested a defective T lymphocyte/macroage interaction in these patients. Alternatively, it could be that the B cells or the glandular epithelial cells of SS patients have the role of macrophages in SS. Thus macrophages are not needed for this immunological response.

No definite differences in the cell composition of the inflammatory lesion were observed between patients with primary SS and SS in association with RA or SLE. Whether this points towards a common tissue reaction with a different clinical or serologic sequelae in the two groups of SS patients deserves further study.

Finally, in our study inappropriate HLA-DR antigen expression was observed in the acini and ducts of minor labial salivary gland biopsy specimens from patients with SS. This finding is in agreement with the recent study of Lindhal et al. Inappropriate HLA-DR antigen expression has also been noted in epithelial cells of the gut, skin, liver, kidney, thyroid, eye, and bronchi in a variety of immunologically mediated conditions such as graft versus host disease and autoimmune states. Whether this is the result or the triggering factor of the inflammatory process is not clear at present. Activated T lymphocytes are present in abundance in the salivary gland lesion of SS. These cells are
probably able to produce γ-interferon, which has been shown to augment HLA-DR antigen expression. Therefore, one might conclude that this HLA-DR expression is the result of the T mediated inflammatory process in SS patients. Alternatively, one can speculate that the absence of macrophages observed in these patients converts epithelial cells into antigen presenting cells, thus inappropriately expressing class II molecules on their surface. This inappropriately HLA-DR expression attracts immunocytes, which in turn, through γ-interferon, augment the HLA-DR expression and thus a vicious circle operates leading to autoimmunity.

We wish to thank Ms E E Papanikolaou for excellent secretarial assistance.

References


HLA-DR expression by labial minor salivary gland tissues in Sjögren’s syndrome.

H M Moutsopoulos, J J Hooks, C C Chan, Y A Dalavanga, F N Skopouli and B Detrick

Ann Rheum Dis 1986 45: 677-683
doi: 10.1136/ard.45.8.677

updated information and services can be found at:
http://ard.bmj.com/content/45/8/677

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/